Clinical trials · Pennsylvania
Non-Hodgkin Lymphoma clinical trials in Pennsylvania
We’re tracking 30 recruiting non-hodgkin lymphoma studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07188090RecruitingPhase 2
Mozobil for stem cell transplant study
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory lymphoma
This trial tests an investigational drug (TLN-121) for people with certain types of lymphoma that have come back or stopped responding to previous treatments. It aims to see if the drug can control the cancer and how safe it is.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06420089RecruitingPhase 1
CAR T cells for T-cell lymphoma
This trial tests a new CAR T-cell treatment for T-cell lymphoma that has come back or hasn't responded to standard treatments. The treatment is designed to target cancer cells that have a protein called CD5 on their surface.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Allentown, PennsylvaniaAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Philadelphia, PennsylvaniaAges birth–18 years - NCT06137144RecruitingPhase 1/Phase 2
AZD3470 for lymphoma that has come back or not responded
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
Philadelphia, PennsylvaniaAges 12 years+ - NCT02848274Recruiting
Looking for factors that predict outcomes in advanced skin lymphoma
This study looks at medical and disease details to find factors that can help predict how advanced mycosis fungoides or Sézary syndrome will behave. Your information may help doctors better estimate prognosis and plan care.
Pittsburgh, PennsylvaniaAges Any age - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Allentown, PennsylvaniaAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Philadelphia, PennsylvaniaAges 1–30
Non-Hodgkin Lymphoma trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting non-hodgkin lymphoma studies listed above.
- Children's Hospital of Philadelphia · 3 studies
- Research Site · 3 studies
- Allegheny Health Network · 2 studies
- University of Pennsylvania · 2 studies
- University of Pennsylvania Hospital · 2 studies
- Abramson Cancer Center at the University of Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania
- Adams Cancer Center
What taking part in a non-hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Non-Hodgkin Lymphoma trials in other states
Common questions
- Are there non-hodgkin lymphoma clinical trials in Pennsylvania?
- Yes. We're currently tracking 30 recruiting non-hodgkin lymphoma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non-hodgkin lymphoma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non-hodgkin lymphoma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.